InvestorsHub Logo

Blue Fin

07/15/20 9:38 PM

#311870 RE: Phoenix300 #311869

You forgot to mention THE MFO'S ARE GONE!!! Like the slithering snakes they are.

Phoenix300

07/15/20 9:38 PM

#311871 RE: Phoenix300 #311869

328,317,492 shares out 81 million market cap.

cybermich

07/15/20 9:49 PM

#311878 RE: Phoenix300 #311869

Celebration?.. lol

I could have asked you the same question the other day when we sold off..
what has changed?

Answer: nothing:)

We still have the RBLs going to bat for us..
We still have statistically signifcant data to back up the Grant application..
We still are looking forward to an eventual FUNDED trial for COVID..
We are still looking forward to Peer Reviews..
We are still looking forward to additional data that will probably inform the above human trial..
We still have all of the other indications for B that the company is still working on..

etc. etc.

You are ABSOLUTELY right:) Nothing has changed.

Justfactsmam

07/15/20 11:28 PM

#311932 RE: Phoenix300 #311869

Small but adequate FDA trial phaseIi would cost between $2-$4M. But that would not necessarily be the cost for IPIX. Grant and shared costs are common. A research hospital with a specific interest in Brilacidin could pay for the entire cost except for the supplying of the drug in the form requested, i e. IV, Pill, or mist Inhaler. The latter would likely involve the research hospital paying the full boat.

Of course all above without considering IPIX being awarded Grant monies.

I have no worries regarding getting to the finish line on current $6M.